Skip to main content
. 2019 Jul 25;142(8):2352–2366. doi: 10.1093/brain/awz202

Figure 1.

Figure 1

Analysis of the correlation of DHC2 expression to MGMT expression and TMZ treatment responses in GBM patients. (A) DYNC2H1/DHC2 expression across glioma tissues of different grades and healthy tissues from the tumour Glioma French-284 database. ns = no significance. (B) DYNC2H1/DHC2 expression across different GBM subtypes in the Glioblastoma TCGA-540 database. (C) qRT-PCR analysis of DYNC2H1 mRNA expression levels in 21 primary GBMs without TMZ treatment and 21 recurrent GBMs with standard TMZ treatment. GAPDH expression was used for normalization. **P < 0.01. (D) Progression-free (progrfree) survival analysis of GBM patients without MGMT promoter methylation using the Glioblastoma TCGA-540 database. (E) Progression-free survival analysis of GBM patients with MGMT promoter methylation using the Glioblastoma TCGA-540 database. (F) Co-expression analysis of DYNC2H1 and MGMT mRNA expression using the Glioblastoma TCGA-provisional database. (G and H) Representative images of immunohistochemical analysis of DYNC2H1 and MGMT in six paired primary and recurrent GBM tissues. Scale bars = 100 μm. H&E = haematoxylin and eosin.